Saxagliptin, alone or in combination (New indication): No fewer complications; more cases of heart failure?

Prescrire International

Volumn 23, Issue 152, 2014, Pages 207-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; HEART FAILURE; HOSPITALIZATION; HUMANS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84906857703     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Prescrire Editorial Staff "Prescrire's advice: do not include gliptins in your prescribing list" Prescrire Int 2013; 22 (135): 37.
2. Prescrire Editorial Staff "Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions" Prescrire Int 2011; 20 (113): 33-37.
3. Prescrire Editorial Staff "Saxagliptin + metformin. Mostly disadvantages" Prescrire Int 2013; 22 (135): 40.
4. Prescrire Rédaction "saxagliptine-Onglyza® en ajout à une insuline. Stop aux gliptines !" Rev Prescrire2010; 32 (349): 811.
5. EMA-CHMP "Type II variation assessment report- Onglyza. EMEA/CHMP/H/C/1039/II/18" 27 June 2013: 46 pages.
6. EMA-CHMP "Type II variation assessment report- Komboglyze/Onglyza. EMEA/H/C/xxxx/WS/295"17 January 2013: 44 pages.
7. EMA-CHMP "Assessment report-Komboglyze. EMEA/H/C/2059/II/4" 20 September 2012: 32 pa ges.
8. Scirica BM et al. "Saxagliptin and cardiovascularoutcomes in patients with type 2 diabetes mellitus"N Engl J Med 2013; 369 (14): 1317-1326.
9. Prescrire Rédaction "4-1-9. Patients sous sitagliptine, vildagliptine, saxagliptine ou linagliptine" RevPrescrire 2013; 33 (362 suppl. Interactions médicamenteuses).